REATA PHARMACEUTICALS INC's ticker is RETA and the CUSIP is 75615P103. A total of 220 filers reported holding REATA PHARMACEUTICALS INC in Q2 2023. The put-call ratio across all filers is 0.91 and the average weighting 0.6%.
Quarter-by-quarter ownership
Value | Shares | Weighting | ||||
---|---|---|---|---|---|---|
Q2 2023 | $666,207 | +113200.5% | 6,534 | +0.9% | 0.00% | 0.0% |
Q1 2023 | $588 | +140.0% | 6,474 | 0.0% | 0.00% | +200.0% |
Q4 2022 | $245 | -99.8% | 6,474 | +17.2% | 0.00% | 0.0% |
Q3 2022 | $138,000 | -27.7% | 5,524 | -12.2% | 0.00% | 0.0% |
Q2 2022 | $191,000 | -4.5% | 6,292 | +2.7% | 0.00% | 0.0% |
Q1 2022 | $200,000 | +525.0% | 6,124 | +389.9% | 0.00% | – |
Q4 2021 | $32,000 | -90.7% | 1,250 | -63.7% | 0.00% | -100.0% |
Q3 2021 | $345,000 | -44.6% | 3,439 | -22.0% | 0.00% | -50.0% |
Q2 2021 | $623,000 | +268.6% | 4,408 | +159.3% | 0.00% | +300.0% |
Q1 2021 | $169,000 | -19.5% | 1,700 | 0.0% | 0.00% | -50.0% |
Q4 2020 | $210,000 | +24.3% | 1,700 | -2.5% | 0.00% | 0.0% |
Q3 2020 | $169,000 | +4125.0% | 1,743 | +6872.0% | 0.00% | – |
Q2 2020 | $4,000 | -33.3% | 25 | -39.0% | 0.00% | – |
Q1 2020 | $6,000 | -40.0% | 41 | -18.0% | 0.00% | – |
Q4 2019 | $10,000 | +150.0% | 50 | 0.0% | 0.00% | – |
Q3 2019 | $4,000 | – | 50 | – | 0.00% | – |
Download |
Other shareholders
Name | Shares | Value | Weighting ↓ |
---|---|---|---|
CPMG Inc | 2,896,901 | $288,821,000 | 55.24% |
PARAGON ASSOCIATES & PARAGON ASSOCIATES II JOINT VENTURE | 100,000 | $9,970,000 | 15.20% |
Tolleson Wealth Management, Inc. | 108,000 | $10,768,000 | 3.25% |
MADDEN SECURITIES Corp | 34,787 | $3,468,000 | 2.03% |
Biondo Investment Advisors, LLC | 101,204 | $10,090,000 | 2.01% |
LBJ Family Wealth Advisors, Ltd. | 30,368 | $3,027,000 | 1.91% |
Duquesne Family Office | 749,897 | $74,765,000 | 1.65% |
Sofinnova Investments, Inc. | 238,520 | $23,780,000 | 1.43% |
Camber Capital Management LP | 400,000 | $39,880,000 | 1.37% |
Integral Health Asset Management, LLC | 44,000 | $4,387,000 | 1.25% |